Close this search box.
Close this search box.

Zantac Cancer Recall: Are You Safe?

By Rheingold Giuffra Ruffo Plotkin & Hellman LLP

NDMA is an extremely potent carcinogen. In recent news, the recall of the over the counter drug, Zantac (ranitidine), was due to the potential carcinogen known as N-nitrosodimethylamine.

Laboratory test findings in the Valisure Pharmacy (2019) and the Stamford/Syracuse University (2016) studies found high levels of ranitidine, a chemical considered a potential carcinogen in humans, including newborn babies. The following are cancers in animals known to be caused by NDMA:

  • Kidney cancer
  • Bladder cancer
  • Liver cancer
  • Pancreas cancer
  • Lung cancer
  • Stomach cancer.
  • Gastric Cancer
  • Colorectal cancer

In the1990s, NDMA was a chemical byproduct. Now it is being tested on animals in laboratory experiments, and the results are cancer-causing. The FDA failed to include this carcinogen on the warning labels, or even to advise the public. Dangers of NDMA within humans were recognized; both the company, the FDA have failed to notify the public.

With extensive research and laboratory experiments, widespread cancers were found present. “Tumors observed in animals are generally assumed to indicate that an agent may produce tumors in humans.” (Environmental Protection Agency).

Another failure of warning to be given by the FDA is the dangers of NDMA while pregnant. Typically Zantac is considered safe to be taken while pregnant; with the recent findings of NDMA, pregnant women are now at risk. Laboratory experiments done on pregnant animals show: that exposure to NDMA while pregnant leads to an increased rate of exposure of kidney and liver cancer to your offspring.

If you think you been affected by Zantac, please call the lawyers at Rheingold Giuffra Ruffo Plotkin & Hellman for a free consultation at (888)260-0473.

Related Posts